A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome

BACKGROUND: Ample evidence indicates the efficacy of serotonin type 3 (5-HT(3)) receptor antagonists in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Mirtazapine is an atypical antidepressant with a well-known 5-HT(3) receptor antagonist property. This study,...

Descripción completa

Detalles Bibliográficos
Autores principales: Khalilian, Alireza, Ahmadimoghaddam, Davoud, Saki, Shiva, Mohammadi, Younes, Mehrpooya, Maryam
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860197/
https://www.ncbi.nlm.nih.gov/pubmed/33536043
http://dx.doi.org/10.1186/s13030-021-00205-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7860197/
https://www.ncbi.nlm.nih.gov/pubmed/33536043
http://dx.doi.org/10.1186/s13030-021-00205-2

Ejemplares similares